Xue Yongjie, Wang Qiulan, He Xuejiao
Department of Pathology, San Ai Tang Hospital Lanzhou, China.
Clinical College, Gansu University of Chinese Tranditional Medicine Lanzhou, China.
Int J Clin Exp Pathol. 2015 Jun 1;8(6):7594-9. eCollection 2015.
Diffuse large B cell lymphoma (DLBCL) is a diffuse proliferation of large neoplastic B lymphoid cells with nuclear size equal to or exceeding that of normal macrophage nuclei. The DLBCL morphological variants are centroblastic, immunoblastic, T-cell- and histiocyte-rich, anaplastic, plasmablastic, anaplastic lymphoma kinase-positive, and primary mediastinal large B-cell lymphoma (PMBCL). These histopathologically-recognized morphological variants respond differently to treatment and have distinct prognoses. We report a case of a 43-year-old patient who presented pain in the lower abdomen that had begun four months prior. Ultrasound-guided biopsy revealed epithelial cell features and a partial alveolar growth pattern. We discovered large diffuse areas comprising large cells with slightly irregular nuclei and very clear cytoplasm. These features were similar to those of clear cell carcinoma in renal tissue, suggesting the possibility of an epithelial neoplasm. To test this possibility, immunohistochemistry for cluster designation markers was performed, but the diffuse areas were found to be positive only for CD45. Additional immunohistochemistry was performed, and the diffuse areas were found to be positive for CD20, CD79a, P53, and Mum-1. Based on these characteristics, a diagnosis of a clear cell variant of DLBCL was made, and the patient was treated with chemotherapy. Precise histological diagnosis is crucial for clinical management and ultimately for patient survival. There has been one additional report of a case of clear cell DLBCL, in outside the mediastinum. The features we identified can be used to define a new subtype of DLBCL. The expression of P53 and Mum-1 suggest a poor prognosis.
弥漫性大B细胞淋巴瘤(DLBCL)是一种大的肿瘤性B淋巴细胞弥漫性增殖,其细胞核大小等于或超过正常巨噬细胞核。DLBCL的形态学变异型包括中心母细胞型、免疫母细胞型、富于T细胞和组织细胞型、间变性、浆母细胞型、间变性淋巴瘤激酶阳性型以及原发性纵隔大B细胞淋巴瘤(PMBCL)。这些在组织病理学上可识别的形态学变异型对治疗的反应不同,预后也不同。我们报告一例43岁患者,其下腹部疼痛始于4个月前。超声引导下活检显示上皮细胞特征和部分肺泡样生长模式。我们发现大片弥漫区域由细胞核略不规则且胞质非常清晰的大细胞组成。这些特征与肾组织中的透明细胞癌相似,提示上皮性肿瘤的可能性。为验证这种可能性,进行了聚类指定标志物的免疫组织化学检测,但发现弥漫区域仅CD45呈阳性。进一步进行免疫组织化学检测,发现弥漫区域CD20、CD79a、P53和Mum-1呈阳性。基于这些特征,诊断为DLBCL透明细胞变异型,该患者接受了化疗。精确的组织学诊断对于临床管理乃至患者生存至关重要。纵隔外另有一例透明细胞DLBCL病例报告。我们所识别的特征可用于定义DLBCL的一种新亚型。P53和Mum-1的表达提示预后不良。